

SECURITIES AND EXCHANGE COMMISSION

FORM 3

Filing Date: **2023-02-09** | Period of Report: **2023-02-09**
SEC Accession No. [0000899243-23-004418](#)

([HTML Version](#) on [secdatabase.com](#))

REPORTING OWNER

Hwang Kuk Hyoun

CIK: **1953660**

Type: **3** | Act: **34** | File No.: **001-41390** | Film No.: **23606945**

Mailing Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

ISSUER

Bellevue Life Sciences Acquisition Corp.

CIK: **1840425** | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**
SIC: **6770** Blank checks

Mailing Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

Business Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004
425-635-7700

FORM 3**UNITED STATES SECURITIES AND
EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVALOMB Number: 3235-0104
Expires: 02/28/2011
Estimated average burden
hours per response 0.5**INITIAL STATEMENT OF BENEFICIAL
OWNERSHIP OF SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the
Investment Company Act of 1940

| | | | |
|---|---|---|---|
| 1. Name and Address of Reporting Person Hwang Kuk Hyoun (Last) (First) (Middle) 10900 NE 4TH STREET, SUITE 2300 (Street) BELLEVUE, WA 98004 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/ Year) 02/09/2023 | 3. Issuer Name and Ticker or Trading Symbol Bellevue Life Sciences Acquisition Corp. [BLAC] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks | 5. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person |
|---|---|---|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|--|---|---|
| Common Stock | 1,725,000 (1) (2) (3) | I | By Bellevue Global Life Sciences Investors LLC |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/ Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|---|--------------------|--|----------------------------------|--|---|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |

Explanation of Responses:

- Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC ("Bellevue Global"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by Bellevue Global.
- Includes up to 225,000 shares subject to forfeiture depending on the extent to which the underwriters' over-allotment is exercised, if at all.
- Includes 680,000 shares of common stock held by Bellevue Global, which pursuant to a convertible promissory note between Bellevue Global and BCM Europe AG, a wholly-owned subsidiary of Bellevue Capital, the principal amount of \$3,400,000 can be converted into 680,000 shares of common stock at the election of Bellevue Global or BCM Europe AG on or after the commencement of the initial public offering of the common stock. Mr. Hwang has voting and dispositive power over the transfer of such shares to BCM Europe.

Remarks:

Chief Executive Officer and President

Signatures

/s/ Kuk Hyoun Hwang

** Signature of Reporting Person

02/09/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.